Genmab A/S
GMABBiotechnology
$56.49−1.40%As of Oct 29vs prior close
- Market cap
- $34.7B
- P/E (TTM)
- 36.4×
- P/E (FY1)
- 48.3×
- From 52W high
- −1.40%
- EPS (YE25)
- $15.37
- Revenue (YE25)
- $3.7B
- Net margin
- 25.89%
- Dividend yield
- 0.00%
Nomior Score
66
Steady ProfileTop 15% of the scored universe
Growth—
Quality80
Value61
Momentum60
Resilience50
Growth
+21.23%revenue a year over 3 fiscal years
YE22 $2.1BYE25 $3.7B
Connections
Revenue to profitYE25
26% of revenue became net profit, down 10 pts on a year.